Facebook
Britain's News Portal
Around The Clock
BREAKING
Loading latest headlines…

Wegovy Cleared for Heart Disease by NICE, Expanding Access to 1.2 Million

Novo Nordisk's weight-loss drug Wegovy has been cleared by NICE for treating heart disease in eligible patients, potentially benefiting 1.2 million people in the UK. This decision marks a significant expansion of the drug's use beyond weight management.

  • NICE has approved Wegovy (semaglutide) for use in patients with heart disease and obesity.
  • The approval could extend access to the drug to an additional 1.2 million people in the UK.
  • Wegovy was initially approved for weight management in 2023.
  • The drug is administered via weekly injection and works by mimicking a hormone that targets appetite regulation.
  • Patients must meet specific criteria, including a BMI of 30 or more (or 27.5 for some ethnic groups) and at least one weight-related comorbidity.

More than one million people with heart disease could soon access a groundbreaking weight-loss injection on the NHS, following a landmark decision by the UK's medicines watchdog. The National Institute for Health and Care Excellence (NICE) has approved Wegovy (semaglutide) for treating cardiovascular disease in certain patients - a move that significantly broadens access beyond its current use for weight management alone.

This expansion means an estimated 1.2 million people across England and Wales who meet specific criteria will now be eligible for the once-weekly injection. For many, this represents a vital new treatment option at the intersection of two major health challenges: obesity and heart disease.

Wegovy works by mimicking GLP-1, a naturally occurring hormone that helps regulate appetite by targeting specific areas of the brain. Originally approved by NICE in 2023 for chronic weight management in adults who are obese or overweight with related health conditions, this latest guidance recognises the drug's broader cardiovascular benefits - particularly important given that obesity significantly increases the risk of heart problems.

Under the new guidelines, patients will be eligible if they have a BMI of 30 kg/m² or above (or 27.5 kg/m² for people of South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean heritage) and established cardiovascular disease. This targeted approach acknowledges that certain ethnic groups face higher risks of diabetes and heart disease at lower BMI thresholds.

For the NHS, this represents both a significant opportunity and a considerable logistical challenge. Whilst offering hope to hundreds of thousands of patients, the health service will need to carefully manage the rollout, ensuring adequate supply chains and monitoring systems are in place for such widespread use.

If you think you might be eligible, speak to your GP about whether Wegovy could be suitable for you. It's important to understand that this isn't a standalone solution - the injection works as part of a comprehensive programme that includes dietary changes and increased physical activity. For more information about weight management or heart health, contact your GP practice or call NHS 111 for guidance.

Why this matters: This approval offers a new treatment pathway for over a million people in the UK struggling with both obesity and heart disease, potentially improving health outcomes and reducing strain on the NHS.

What this means for you: Eligible patients with heart disease may now access Wegovy through the NHS, though expect lengthy waiting lists as the health service manages demand for 1.2 million potential users. Your GP will need to assess whether you meet the strict criteria before referring you to specialist weight management services for this treatment.

Related Articles

Get the news that matters.

Join thousands of readers getting the best of British news straight to their inbox.